Program
Roflumilast
Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.
Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 340 open or running | phase 4since Mar 30, 2011 | Jun 9, 2003 | none ahead |
| Arcutis Biotherapeuticsits history only | 181 open or running | phase 3since Dec 23, 2019 | Dec 29, 2017 | Apr 27, 2028phase 3 · NCT07916480 |
| Huadong Medicineits history only | 31 open or running | phase 3since Sep 30, 2024 | Sep 30, 2024 | Jun 30, 2027phase 3 · NCT07683806 |
| FLUIDDA nvits history only | 20 open or running | phase 4since Nov 21, 2011 | Nov 21, 2011 | none ahead |
| Integrative Skin Science and Researchits history only | 11 open or running | phase 4since Apr 23, 2026 | Apr 23, 2026 | Aug 2027phase 4 · NCT07560618 |
| Padagisits history only | 10 open or running | phase 3since Feb 28, 2023 | Feb 28, 2023 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 2since Jan 25, 2016 | Jan 25, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Mar 4, 2014 | Mar 4, 2014 | none ahead |
Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sino Biopharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2016First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT02671942 · 55 enrolled · China
TargetBeta
“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
The one study Sino Biopharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02671942Pulmonary Disease, Chronic Obstructive · China | 2 | Terminated | Jun 13, 2018 | 55 |
How it is read
Names in the registry
- “Roflumilast”, 37 entries
- “Roflumilast Cream 0.15%”, 5 entries
- “Roflumilast Cream 0.3%”, 3 entries
- “ARQ-151 cream 0.05%”, 2 entries
- “Roflumilast Foam 0.3%”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 21 studies
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Asthma, 8 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.